logo
Select company
Select metric
$ -111.9MNet Cash Flow - Change in Cash & Cash Equivalents
VS
Market
11
Sector
9
Industry
8
History
25
$ 9.84Close
$ 2.51 - $ 10.09 52-Week Range
Ticker Information

Ticker

FDMT

Company Name

4D MOLECULAR THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

4D MOLECULAR THERAPEUTICS INC - Net Cash Flow - Change in Cash & Cash Equivalents Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

FDMT - CF - Chg. Cash Historical data
DateNet Cash Flow - Change in Cash & Cash Equivalents
6/30/2025$ -111.9M
3/31/2025$ -142.07M
12/31/2024$ -99.77M
9/30/2024$ -88.14M
6/30/2024$ -47.25M
3/31/2024$ 197.03M
12/31/2023$ 196.76M
9/30/2023$ 167.38M
6/30/2023$ 122.83M
3/31/2023$ 2.6M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • 4D MOLECULAR THERAPEUTICS INC's latest trailing twelve months (TTM) CF - Chg. Cash stands at $ 227.07M.
  • Over the past 5 years, 4D MOLECULAR THERAPEUTICS INC's average CF - Chg. Cash has been $ -5.56M.
  • The median CF - Chg. Cash for 4D MOLECULAR THERAPEUTICS INC during this period was $ -47.25M
  • 4D MOLECULAR THERAPEUTICS INC reached its highest CF - Chg. Cash over the past 5 years at $ 227.07M.
  • The lowest CF - Chg. Cash recorded by 4D MOLECULAR THERAPEUTICS INC in the same timeframe $ -183.9M

4D MOLECULAR THERAPEUTICS INC's CF - Chg. Cash vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

CF - Chg. Cash Benchmarks
CompanyCF - Chg. Cash
ALT : ALTIMMUNE INC $ 125.98MLYEL : LYELL IMMUNOPHARMA INC $ -33.32MLXEO : LEXEO THERAPEUTICS INC $ -139.5MNMRA : NEUMORA THERAPEUTICS INC $ -27.37MANNX : ANNEXON INC $ -25.01MDMAC : DIAMEDICA THERAPEUTICS INC $ -9.96MAARD : AARDVARK THERAPEUTICS INC -AVIR : ATEA PHARMACEUTICALS INC $ -155.67MGALT : GALECTIN THERAPEUTICS INC $ -11.83MJBIO : JADE BIOSCIENCES INC $ 154.24M

Definition of Net Cash Flow - Change in Cash & Cash Equivalents

[Cash Flow Statement] Represents the amount of increase (decrease) in cash and cash equivalents. Includes cash from operations [NCFO], investing [NCFI] and financing [NCFF], adjusted for the effect of exchange rate changes on cash [NCFX]

FDMT - Net Cash Flow - Change in Cash & Cash Equivalents, Last 5 years

$ -183.9M

Minimum

Mar 31, 2022

$ 227.07M

Maximum

Dec 31, 2020

$ -5.56M

Average

$ -47.25M

Median

CF - Chg. Cash Benchmark Analysis

The chart above depicts the distribution of CF - Chg. Cash for companies in the Total Stock Market. The average CF - Chg. Cash of the companies is $ 1.18M with a standard deviation of $ 44.92M.
The following table provides additional summary stats:
CF - Chg. Cash in the Market:
filtered constituents3.34K
min$ -136.09M
max$ 137.58M
average$ 1.18M
median$ 115.89K
std$ 44.92M